Highest-materiality recent filing
Protagenic Therapeutics unwinds Phytanix Bio acquisition, pays $310k, settles litigation
Settlement and Unwind Agreement executed Feb 17, 2026; SEA dated May 15, 2025 terminated.
Protagenic Therapeutics receives Nasdaq delisting notice; trading to move to OTC Jan 5, 2026
Nasdaq determined to delist PTIX and PTIXW due to failure to meet minimum stockholders' equity (Rule 5550(b)(1)) and timely filing (Rule 5250(c)(1)).
Protagenic Therapeutics receives Nasdaq delisting notice for equity and filing non-compliance
Stockholders' equity fell below $2.5M minimum per Listing Rule 5550(b)(1) as of June 30, 2025.
Protagenic Therapeutics files suit to rescind Phytanix Bio acquisition or seek damages
Filed Verified Complaint in Delaware Chancery Court on October 28, 2025.
Protagenic restructures after Phytanix acquisition; CEO/COO out, targets $8M savings
Acquired Phytanix Bio on May 15, 2025 via share exchange; gained five preclinical candidates (PHYX-001 to -005).
Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete
Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.
Protagenic Therapeutics restructures, cuts ~$8M annual costs; CEO and COO terminated
Board approved restructuring to virtual model, focusing on PT00114 Phase 2 trial expected to complete in 9–12 months.
Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises
Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.
Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors
Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025
Protagenic Therapeutics approves 1-for-14 reverse stock split effective May 5, 2025
Reverse stock split at 1-for-14 ratio, effective 12:01 a.m. ET on May 5, 2025.
Protagenic shareholders approve reverse stock split at ratio 1:10 to 1:20
Special Meeting held April 18, 2025; 4,049,963 shares present out of 7,241,443 entitled.
Protagenic receives Nasdaq delisting notice for failing to regain $1 bid price compliance
Nasdaq notified on Jan 22, 2025 that company failed to regain compliance with minimum bid price Rule 5550(a)(2).
Protagenic Therapeutics appeals Nasdaq delisting; hearing set for Jan 30, 2025
Nasdaq determined non-compliance with $2.5M stockholders' equity requirement (Rule 5550(b)(1)).
Protagenic Therapeutics receives Nasdaq delisting notice; stock suspension set for Nov 29
Failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement by Nov 18, 2024, after extension.
Protagenic Therapeutics closes $1.275M private placement of common stock and warrants
Closed private placement on Nov 4, 2024; sold 1,948,295 shares of common stock.
Protagenic Therapeutics updates PT00114 milestones: Phase I multi-dose Q4 2024, Phase IIa Q3 2025
Multiple dose portion of Phase I study for PT00114 expected to commence Q4 2024.
Nasdaq notified PTIX on July 24, 2024 of non-compliance with minimum $1.00 bid price for 30 consecutive business days.
Protagenic Therapeutics receives Nasdaq deficiency notice for failing minimum equity requirement
Company's stockholders' equity fell below Nasdaq's $2.5M minimum as of March 31, 2024.
Phase 1 single dose trial completed with 30 subjects across five cohorts up to 1,000 micrograms; no clinically-relevant adverse events.
Protagenic Therapeutics resolves Nasdaq delisting notice, regains compliance with bid price rule
Regained compliance with Nasdaq Listing Rule 5550(a)(2) on March 19, 2024.
Protagenic Therapeutics receives Nasdaq minimum bid price deficiency notice
Nasdaq notified PTIX on Nov 21, 2023 that common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.
Reverse split effective 5:01 p.m. ET March 22, 2023; split-adjusted trading Nasdaq opens March 23, 2023.
Protagenic Therapeutics delays PT00114 trial start to Jan 2022; Q2 net loss $2.6M
FDA required ready-to-inject vials; IND re-filing moved to Q4 2021, Phase I/IIa start to Jan 2022.
Protagenic Therapeutics delays PT00114 clinical trial start to Q4 2021 after FDA request
FDA requested ready-to-inject clinical vials instead of local formulation; company refiling IND.
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
Colin Stott as Chief Operating Officer and as a director of the Company
Colin Stott as Chief Operating Officer and as a director of the Company
Jennifer Chao as a director of the Company
appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company
appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
promoted Andrew Slee from his prior role of Chief Operating Officer to the Company’s Chief Development Officer, effective immediately upon the Closing on May 15, 2025
Max materiality 0.90 · Median 0.60 · Most common event other_material